Caricamento azienda
Scribe Therapeutics, Inc.
SCTX · Nasdaq · ·
23,01 USD+5,6%chiusura 29 set
- 1M
- -19,1%
SCTX · Nasdaq · ·
23,01 USD+5,6%chiusura 29 set
Dal 8-K dell’azienda.
Per Scribe Therapeutics, Inc. non è disponibile alcuna trascrizione di conference call sui risultati.
“The second quarter and the weeks immediately following represented a transformational period for Scribe,”
Citato alla lettera dal comunicato, e mostrato solo quando il documento lo attribuisce a una persona con nome e cognome.
I comunicati escono dopo la chiusura o prima dell’apertura, quindi il movimento è quello della seduta successiva.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com .
La descrizione dell’azienda stessa, come compare in calce al comunicato.
La citazione e la descrizione della società provengono dall’8-K relativo all’Item 2.02 depositato da Scribe Therapeutics, Inc. il 2 settembre 2026; la tabella è costruita dai suoi rapporti trimestrali. Leggi il comunicato su EDGAR I prezzi sono rettificati per frazionamenti e dividendi.